Patents by Inventor Fanglong Yang

Fanglong Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10906905
    Abstract: The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring bridged ring derivative as shown in formula (I), a preparation method therefor and a pharmaceutical composition comprising the derivative, and the use thereof as a therapeutic agent, in particular as a TGF-? inhibitor, and the use in the preparation of a drug for treating, preventing or reducing cancers mediated by the over-expression of TGF-?, wherein the definition of each substituent in the general formula (I) is the same as defined in the description.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: February 2, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai Yu, Fanglong Yang, Jingjing Yan, Xiao Wu, Feng He, Weikang Tao
  • Patent number: 10899741
    Abstract: The present invention relates to a 3,4-bipyridyl pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new 3,4-bipyridyl pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, a use of the derivative as a therapeutic agent, in particular as a TGF-? inhibitor, and a use of the derivative in the preparation of a drug which treats, prevents or reduces cancer mediated by TGF-? overexpression. The substituents in formula (I) have the same definitions as in the description.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 26, 2021
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Guangyuan Shen, Feng He, Weikang Tao
  • Publication number: 20200199115
    Abstract: The present invention relates to an oxopicolinamide derivative, a preparationmethod therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Fanglong YANG, Weimin WANG, Xiaodong LI, Gang CHEN, Feng HE, Weikang TAO
  • Patent number: 10633375
    Abstract: The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 28, 2020
    Assignees: Jinagsu Hengrui Medicine Co., Ltd, Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Weimin Wang, Xiaodong Li, Gang Chen, Feng He, Weikang Tao
  • Publication number: 20200055852
    Abstract: The present invention relates to a five-membered heteroaryl ring bridged ring derivative, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a new five-membered heteroaryl ring bridged ring derivative as shown in formula (I), a preparation method therefor and a pharmaceutical composition comprising the derivative, and the use thereof as a therapeutic agent, in particular as a TGF-? inhibitor, and the use in the preparation of a drug for treating, preventing or reducing cancers mediated by the over-expression of TGF-?, wherein the definition of each substituent in the general formula (I) is the same as defined in the description.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 20, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai YU, Fanglong YANG, Jingjing YAN, Xiao WU, Feng HE, Weikang TAO
  • Patent number: 10562977
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 18, 2020
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali Wang, Lianshan Zhang, Jindong Liang, Ang Li, Fanglong Yang
  • Publication number: 20190270724
    Abstract: The present invention relates to a 3,4-bipyridyl pyrazole derivative, and a preparation method therefor and a medical application thereof. Specifically, the present invention relates to a new 3,4-bipyridyl pyrazole derivative as shown in formula (I), a preparation method for the derivative, a pharmaceutical composition containing the derivative, a use of the derivative as a therapeutic agent, in particular as a TGF-? inhibitor, and a use of the derivative in the preparation of a drug which treats, prevents or reduces cancer mediated by TGF-? overexpression. The substituents in formula (I) have the same definitions as in the description.
    Type: Application
    Filed: November 13, 2017
    Publication date: September 5, 2019
    Inventors: Fanglong Yang, Ling Zhang, Guangyuan Shen, Feng He, Weikang Tao
  • Patent number: 10398689
    Abstract: The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: September 3, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Ling Zhang, Chunfei Wang, Mingxun He, Qiyue Hu, Feng He, Weikang Tao, Piaoyang Sun
  • Patent number: 10385060
    Abstract: The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: August 20, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hangrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai Yu, Fanglong Yang, Lei Chen, Jingjing Yan, Xiqian Zhang, Zhichao Xie, Lingxiang Chen, Mingxun He
  • Publication number: 20190185464
    Abstract: The present invention relates to an oxopicolinamide derivative, a preparation method therefor and the pharmaceutical use thereof. In particular, the present invention relates to an oxopicolinamide derivative as shown in the general formula (AI), a preparation method therefor and a pharmaceutical composition comprising the derivative, and to the use thereof as a therapeutic agent, in particular as an inhibitor of blood coagulation factor XIa (Factor XIa, FXIa for short) and the use thereof in the preparation of a drug for treating diseases such as thromboembolism, wherein the definition of each substituent in the general formula (AI) is the same as defined in the description.
    Type: Application
    Filed: August 30, 2017
    Publication date: June 20, 2019
    Inventors: Fanglong YANG, Weimin WANG, Xiaodong LI, Gang CHEN, Feng HE, Weikang TAO
  • Publication number: 20180318284
    Abstract: The present invention relates to a benzopiperidine derivative, a preparation method thereof and a medical use thereof. In particular, the present invention relates to a benzopiperidine derivative as shown by general formula (I), a preparation method thereof and a pharmaceutical composition containing the derivative, as well as a use thereof as an estrogen receptor modulator in the prevention and/or treatment of estrogen receptor-mediated or dependent diseases or conditions. Preferably, the disease is breast cancer. The substituents in the general formula (I) are the same as those defined in the description.
    Type: Application
    Filed: December 2, 2016
    Publication date: November 8, 2018
    Inventors: Fanglong YANG, Ling ZHANG, Chunfei WANG, Mingxun HE, Qiyue HU, Feng HE, Weikang TAO, Piaoyang SUN
  • Publication number: 20180298020
    Abstract: The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 18, 2018
    Inventors: Shanghai YU, Fanglong YANG, Lei CHEN, Jingjing YAN, Xiqian ZHANG, Zhichao XIE, Lingxiang CHEN, Mingxun HE
  • Patent number: 10087191
    Abstract: The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 2, 2018
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai Yu, Fanglong Yang, Lei Chen, Jingjing Yan, Xiqian Zhang, Zhichao Xie, Lingxiang Chen, Mingxun He
  • Publication number: 20180170943
    Abstract: The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 21, 2018
    Inventors: Shanghai YU, Fanglong YANG, Lei CHEN, Jingjing YAN, Xiqian ZHANG, Zhichao XIE, Lingxiang CHEN, Mingxun HE
  • Publication number: 20170002090
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Application
    Filed: January 22, 2015
    Publication date: January 5, 2017
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali WANG, Lianshan ZHANG, Jindong LIANG, Ang LI, Fanglong YANG
  • Patent number: 9139548
    Abstract: Disclosed in the present invention are polycyclic derivatives as represented by general formula (I), the preparation method thereof, pharmaceutical compositions containing the derivatives and uses thereof as therapeutic agents, especially the GPR40 agonist and in preparation of drugs for treating diseases such as diabetes and metabolic disorders, etc., wherein each substituent in the general formula (I) has the same definition as in the description.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: September 22, 2015
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Fanglong Yang, Qing Dong, Jihui Han, Chunfei Wang, Ling Zhang, Yang Wang
  • Publication number: 20150005282
    Abstract: Disclosed in the present invention are polycyclic derivatives as represented by general formula (I), the preparation method thereof, pharmaceutical compositions containing the derivatives and uses thereof as therapeutic agents, especially the GPR40 agonist and in preparation of drugs for treating diseases such as diabetes and metabolic disorders, etc., wherein each substituent in the general formula (I) has the same definition as in the description.
    Type: Application
    Filed: December 27, 2012
    Publication date: January 1, 2015
    Inventors: Fanglong Yang, Qing Dong, Jihui Han, Chunfei Wang, Ling Zhang, Yang Wang
  • Patent number: 8609622
    Abstract: C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof are disclosed. In particular, C-aryl glucoside derivatives represented by formula (I), with each substituent defined in the application, pharmaceutically acceptable salts or stereoisomers thereof, their preparation methods, and pharmaceutical compositions containing the derivatives as well as their uses as therapeutic agents, particularly as sodium-dependent glucose cotransporter (SGLT)-1 inhibitors, are disclosed.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: December 17, 2013
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Fanglong Yang, Peng Cho Tang, Qing Dong, Wangyang Tu, Jiang Fan, Dongliang Guan, Guangyuan Shen, Yang Wang, Jijun Yuan, Limin Zhang
  • Patent number: 8518946
    Abstract: Pharmaceutically acceptable salts of (R)-7-[3-amino-4-(2,4,5-trifluorophenyl)-butyryl]-3-trifluoromethyl-5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-formic acid, their preparation methods, compositions containing the said pharmaceutical salts and their use as medicaments, especially as dipeptidyl peptidase IV (DPP-IV) inhibitors are disclosed. Of the many acceptable salts, one example is the following.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: August 27, 2013
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Peng Cho Tang, Piaoyang Sun, Fanglong Yang, Jindong Liang, Guangyuan Shen, Yang Wang, Jiang Fan
  • Patent number: 8513411
    Abstract: Tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), their preparation methods, pharmaceutical compositions containing the derivatives and uses thereof as medicaments, especially as dipeptidyl peptidase IV inhibitors, wherein the substituents of formula (I) are defined as same as the description.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: August 20, 2013
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Peng Cho Tang, Fanglong Yang, Jiang Fan, Hu Feng, Yang Wang, Tao Yang